A Study of HLX07 + HLX10 With or Without Chemotherapy Versus HLX10 With Chemotherapy in First Line sqNSCLC

Squamous Non-small-cell Lung Cancer Clinical Trial

Official title:
A Randomized, Open-Label, Multicenter, Phase II Study of HLX07 (Anti-EGFR Antibody) +HLX10 (Anti-PD-1 Antibody) With or Without Chemotherapy Versus HLX10 With Chemotherapy in First Line sqNSCLC

Status Recruiting

Clinical Trial Summary

The purpose of this study is to evaluate the clinical efficacy and safety of HLX07 In Combination with HLX10 with or without Chemotherapy versus HLX10 with Chemotherapy in First Line Recurrent or Metastatic Squamous Non-Small Cell Lung Cancer.This study consists of three periods, screening period (28 days), treatment period and follow-up period (including safety follow-up, survival follow-up).Subjects can be enrolled into this study only if they meet inclusion criteria and do not meet exclusion criteria.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Carcinoma, Non-Small-Cell Lung
Squamous Non-small-cell Lung Cancer

Clinical Trial Details

NCT number	NCT04976647
Study type	Interventional
Source	Shanghai Henlius Biotech
Contact
Status	Recruiting
Phase	Phase 2
Start date	January 18, 2022
Completion date	October 30, 2024

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04474119` - KN046 in Subjects With Advanced Squamous Non-small Cell Lung Cancer	Phase 3
Recruiting	`NCT05902988` - A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer	Phase 1/Phase 2
Active, not recruiting	`NCT04432207` - A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer	Phase 1
Active, not recruiting	`NCT02996214` - Paclitaxel Liposome for Squamous Non-Small-cell Lung Cancer Study(LIPUSU)	Phase 4
Active, not recruiting	`NCT06307093` - Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant Neoplasms	Phase 1
Terminated	`NCT05275673` - A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer	Phase 2